{"organizations": [], "uuid": "eb203c494e26dd0f58bfed2f5700cb3e6f7a10a3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/22/globe-newswire-pacific-biosciences-of-california-inc-fourth-quarter-and-year-end-2017-financial-results-call.html", "country": "US", "domain_rank": 767, "title": "Pacific Biosciences of California, Inc. Fourth Quarter and Year-End 2017 Financial Results Call", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T01:43:00.000+02:00", "replies_count": 0, "uuid": "eb203c494e26dd0f58bfed2f5700cb3e6f7a10a3"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/22/globe-newswire-pacific-biosciences-of-california-inc-fourth-quarter-and-year-end-2017-financial-results-call.html", "ord_in_thread": 0, "title": "Pacific Biosciences of California, Inc. Fourth Quarter and Year-End 2017 Financial Results Call", "locations": [], "entities": {"persons": [], "locations": [{"name": "menlo park", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "nasda", "sentiment": "negative"}, {"name": "pacific biosciences of california, inc.", "sentiment": "neutral"}, {"name": "pacific biosciences of california, inc", "sentiment": "neutral"}, {"name": "pacb", "sentiment": "none"}, {"name": "pacific biosciences pacific biosciences of california, inc.", "sentiment": "none"}, {"name": "eastern time", "sentiment": "none"}, {"name": "pacific biosciences", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MENLO PARK, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its Fourth Quarter and Year-End 2017 Financial Results on Thursday, February 1, 2018, at 4:30pm Eastern Time.\nThe call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/ .\nDate: February 1, 2018\nTime: 4:30pm ET\nListen via Internet: http://investor.pacificbiosciences.com/\nToll-free: 888.366.7247\nInternational: 707.287.9330\nConference ID: 9367938\nReplay: http://investor.pacificbiosciences.com\nAbout Pacific Biosciences\nPacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT ® ) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio ® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com .\nContact: Pacific Biosciences\nTrevin Rard\n650.521.8450\nir@pacificbiosciences.com\nSource:Pacific Biosciences, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/6ee0cce4-5b97-455e-b36e-da7145a4453e", "https://www.globenewswire.com/Tracker?data=T8geBrlwxmppZx4WXmpFnQdeLyOJIRjcouLdnxDawOGDg0oqf3-VlTrXW4N7r4Rv-jvgrLmbj-ebCzzeQF8bTu8-1fPhYaxrQaDUhrhg6PhZxnXpAof6SSdZ_v9W-xkJZxqjoP1nTHOs74XMTTXyUg==", "https://www.globenewswire.com/Tracker?data=T8geBrlwxmppZx4WXmpFnQdeLyOJIRjcouLdnxDawOGDg0oqf3-VlTrXW4N7r4RvfSfcZJ2MDGBeH9_GSqYXWEK6yzC_tbe_3xi9EYec1qN8bI4zADnOcDwHg8Q102eMU9C8nW93Aioh2EuTA64O5w==", "https://www.globenewswire.com/Tracker?data=nMChHzuxifPMMCm7FQqpA4wjbl_XYGKQXWrQcdDP7GxnDQZsjE3gR7itSTvA2aOvhSls0TZI3dEBoX0Dp8tSuGA6LOjLT-Kw74W0fSRanKI=", "http://investor.pacificbiosciences.com/", "https://www.globenewswire.com/Tracker?data=T8geBrlwxmppZx4WXmpFnQdeLyOJIRjcouLdnxDawOGDg0oqf3-VlTrXW4N7r4RvqFvuLfnSldqpbhfH6ityses499SUZpuykzIKxSblsGWFJmPAfwtyd_u5XeiH3MpLQgaJ2-0fwa8MyTA6IPL2gA==", "https://www.globenewswire.com/Tracker?data=s4r2pMOgJp0jiPse_UlGsMDln2jMkI_vvjwGbDCj3Hv0fJ6gZ2jVRSe1YqqZyo42-sSW19uofubyRAjRVZliKCTJQ1oRKpsmZ5xTgbKaX71hVc9RDOTwYXIz0QGgnGY-U-dCstGE9OLs8ZFqzAQmE_lIbE5nNZczMcleMWiDb3bhlchS9RI16JMrO8eQ9_TDgS3Gt0EnRjRgGYfHGyp6_gz0YUITINseSCjjQ-odC68ngdOx1n03L0zdQmKfy1c9NUPIGbQmKR8DPvCM9gKfr3uvimFZtvcCxx83ZrjgKEqK4XTHggN6LId9BLMi5mmKrKV6roN5IPb36ZU1JRMMnjT-_KAKLYUdbQrMJNWggbk="], "published": "2018-01-23T01:43:00.000+02:00", "crawled": "2018-01-23T04:04:34.098+02:00", "highlightTitle": ""}